Quest Diagnostics (DGX) Stock Price, News & Analysis

Company Overview

Quest Diagnostics (NYSE: DGX) is a provider of diagnostic information services, conducting laboratory tests that help physicians and other health care professionals diagnose, monitor and manage medical conditions. Its services include routine blood and other clinical laboratory testing, anatomic pathology, and specialized molecular and genetic testing.

The company serves patients, physicians, hospitals, health plans, employers and government organizations. In addition to testing performed through its laboratories and patient service centers, Quest offers services such as workplace drug testing and diagnostic support for clinical research.

Quest Diagnostics traces its roots to a clinical laboratory established in 1967 and became an independent company in 1996 after being spun off from Corning. It operates primarily in the United States and also has select international operations. Jim Davis serves as the company’s chairman and chief executive officer.

Key Stats

• Today's Range: $258.56 to $260.91
• 50-Day Range: $226.94 to $259.46
• 52-Week Range: $171.18 to $262.00
• Volume: 649,370 shs
• Average Volume: 975,742 shs
• Market Capitalization: $28.55 billion
• P/E Ratio: 25.84
• Dividend Yield: 1.33%
• Price Target: $248.70
• Consensus Rating: Moderate Buy

Quest Diagnostics Stock Analysis - MarketRank™

Quest Diagnostics scored higher than 76% of companies evaluated by MarketBeat, and ranked 239th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Quest Diagnostics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 1 strong buy rating, 3 buy ratings, 5 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Quest Diagnostics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Quest Diagnostics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.40%

Earnings Growth

Earnings for Quest Diagnostics are expected to grow by 5.40% in the coming year, from $11.29 to $11.90 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Quest Diagnostics is 25.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 26.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quest Diagnostics is 25.84, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.56.

Price to Earnings Growth Ratio

Quest Diagnostics has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Quest Diagnostics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.42% of the float of Quest Diagnostics has been sold short.

Short Interest Ratio / Days to Cover

Quest Diagnostics has a short interest ratio ("days to cover") of 3.64, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Quest Diagnostics has recently increased by 4.48%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Quest Diagnostics pays a meaningful dividend of 1.32%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Quest Diagnostics has been increasing its dividend for 14 years.

Dividend Coverage

The dividend payout ratio of Quest Diagnostics is 34.26%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Quest Diagnostics will have a dividend payout ratio of 28.91% next year. This indicates that Quest Diagnostics will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.61

News Sentiment

Quest Diagnostics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 28 news articles for Quest Diagnostics this week, compared to 6 articles on an average week.

Search Interest

9 people have searched for DGX on MarketBeat in the last 30 days. This is an increase of 29% compared to the previous 30 days.

MarketBeat Follows

3 people have added Quest Diagnostics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Quest Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,730,269.00 in company stock.

Percentage Held by Insiders

0.88% of the stock of Quest Diagnostics is held by insiders.

Percentage Held by Institutions

88.06% of the stock of Quest Diagnostics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 10/21 Dividend: 10/06/2026
• Ex-Dividend for 10/21 Dividend: 10/06/2026
• Dividend Payable: 10/21/2026
• Last Earnings: 10/22/2026
• Today: 11/15/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• 9th Annual Evercore ISI HealthCONx Conference: 12/01/2026
• 38th Annual Healthcare Conference: 12/01/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NYSE:DGX
• CIK: 1022079
• Web: www.questdiagnostics.com
• Phone: (973) 520-2700
• Fax: 201-462-4169
• Employees: 57,000
• Year Founded: 1967

Price Target and Rating

• Average Price Target for Quest Diagnostics: $248.70
• High Price Target: $262.00
• Low Price Target: $215.00
• Potential Upside/Downside: -4.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $10.04
• Trailing P/E Ratio: 25.84
• Forward P/E Ratio: 21.80
• P/E Growth: 2.32
• Net Income: $992 million
• Net Margins: 9.53%
• Pretax Margin: 12.60%
• Return on Equity: 16.21%
• Return on Assets: 7.41%

Debt

• Debt-to-Equity Ratio: 0.70
• Current Ratio: 1.70
• Quick Ratio: 1.58

Sales & Book Value

• Annual Sales: $11.04 billion
• Price / Sales: 2.59
• Cash Flow: $15.16 per share
• Price / Cash Flow: 17.11
• Book Value: $72.26 per share
• Price / Book: 3.59

Miscellaneous

• Outstanding Shares: 110,020,000
• Free Float: 109,051,000
• Market Cap: $28.55 billion
• Optionable: Optionable
• Beta: 0.55